BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans
These findings establish lncRNAs as key regulators of tumor immunity and uncover a critical link between genetic risk, lncRNAs, cancer immunosurveillance and breast cancer development, positioning BRRIAR as a promising lncRNA-based RIG-I activator for ER + breast cancer therapy.
Authors
- Sarah Alexandrou (ORCID: https://orcid.org/0000-0003-1186-6507)
- Michelle Wykes (ORCID: https://orcid.org/0000-0002-7956-0144)
- Juliet D. French (ORCID: https://orcid.org/0000-0002-9770-0198)
- Rakesh N. Veedu (ORCID: https://orcid.org/0000-0003-2192-9532)
- Deshapriya S. Karunarathne
- Mainá Bitar (ORCID: https://orcid.org/0000-0003-4103-8008)
- Lu Qian Wang
- Susanne Kaufmann
- Sébastien Jacquelin (ORCID: https://orcid.org/0000-0001-5087-3641)
- Rebekah Ziegman (ORCID: https://orcid.org/0000-0002-2343-9839)
- Stacey L. Edwards (ORCID: https://orcid.org/0000-0001-7428-4139)
- Kristine Hillman (ORCID: https://orcid.org/0000-0003-3039-4437)
- Haran Sivakumaran (ORCID: https://orcid.org/0000-0002-4691-4989)
- Sneha Nair
- Isela Sarahi Rivera
- Jonathan Beesley
- C. Elizabeth Caldon
- Xue Lu
- P. Prakrithi
- Ji Liu
- Quan H. Nguyen
- Wei Shi
Institutions
- Garvan Institute of Medical Research (AU)
- Queensland University of Technology (AU)
- The University of Queensland (AU)
- Murdoch University (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Mater Research (AU)
- Perron Institute for Neurological and Translational Science (AU)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1186/s12943-025-02510-8
- Primary Topic
- Cancer-related molecular mechanisms research
- Type
- article
- Field-Weighted Citation Impact
- 0.00